Clinical utility of CLIA-Grade AR-V7 testing in patients with metastatic castration-resistant prostate cancer

Nursing and Health Professions

• Chemiluminescence Immunoassay 100%
• Castration Resistant Prostate Cancer 100%
• Abiraterone 100%
• Enzalutamide 100%
• Chemotherapy 66%
• Clinical Trial 66%
• Clinical Practice 33%
• Clinical Laboratory 33%
• Clinical Decision Making 33%
• Prostate Cancer 33%
• Prostate Specific Antigen 33%
• Prevalence 33%
• Androgen Receptor 33%
• Messenger RNA 33%

Medicine and Dentistry

• Circulating Tumor Cell 100%
• Castration Resistant Prostate Cancer 100%
• Chemiluminescence Immunoassay 100%
• Targeted Therapy 60%
• Abiraterone 60%
• Enzalutamide 60%
• Clinical Trial 40%
• Chemotherapy 40%
• Prostate Cancer 20%
• Androgen Receptor 20%
• Prevalence 20%
• Clinical Decision Making 20%
• Prostate Specific Antigen 20%
• Antigen Response 20%
• Messenger RNA 20%

Keyphrases

• Clinical Utility 100%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 100%
• AR-V7 100%
• Circulating Tumor Cells 38%
• Enzalutamide 23%
• Abiraterone 23%
• AR-targeted Therapy 23%
• Clinical Trials 15%
• Taxane Chemotherapy 15%
• United States 7%
• Androgen Receptor 7%
• Improved Outcomes 7%
• Clinical Practice 7%
• Canada 7%
• Johns Hopkins University 7%
• Clinical Grade 7%
• Prior Exposure 7%
• Nave 7%
• Messenger RNA Expression 7%
• Questionnaire Survey 7%
• Change Management 7%
• Clinical Laboratory Improvement Amendments 7%
• Prostate-specific Antigen Response 7%
• Taxane Therapy 7%
• Overall Management 7%
• Clinical Decision-making 7%
• Splice Variants 7%